RedHill Biopharma Ltd.

NASDAQ: RDHL · Real-Time Price · USD
1.37
-0.02 (-1.44%)
At close: Aug 15, 2025, 3:59 PM
1.39
1.36%
After-hours: Aug 15, 2025, 06:45 PM EDT

RedHill Biopharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
8.04M 6.51M 61.8M 85.76M
Cost of Revenue
3.19M 3.46M 33.34M 49.41M
Gross Profit
4.85M 3.05M 28.46M 36.35M
Operating Income
-14.61M 12.63M -42.84M -81.14M
Interest Income
133.63K 93.76K 139.45K 51K
Pretax Income
-8.27M 23.95M -71.67M -97.74M
Net Income
-8.27M 23.92M -71.67M -97.74M
Selling & General & Admin
15.52M 30.98M 64.03M 87.99M
Research & Development
1.59M 3.53M 7.28M 29.5M
Other Expenses
2.36M -44.06M n/a n/a
Operating Expenses
19.46M -9.56M 71.31M 117.49M
Interest Expense
530.5K 426.9K 484.1K 16.57M
Selling & Marketing Expenses
1M 2.1M 9.06M 11.38M
Cost & Expenses
22.66M -6.1M 104.64M 166.89M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
2.46M 518.24K 123.86K 93.05K
Shares Outstanding (Diluted)
2.46M 518.24K 123.86K 93.05K
EPS (Basic)
-3 46.00 -600 -1K
EPS (Diluted)
-3 46.00 -600 -1K
EBITDA
-7.59M 26.27M -42.84M -63.03M
EBIT
-8.21M 24.28M -30.34M -81.18M
Depreciation & Amortization
619K 1.99M 8.12M 18.16M